ScoreWhy is Vaishali Pharma Ltd ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 7.02%
- Poor long term growth as Net Sales has grown by an annual rate of 13.04% and Operating profit at 0.90% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.83
2
Positive results in Jun 26
- ROCE(HY) Highest at 8.38%
- OPERATING PROFIT TO NET SALES(Q) Highest at 6.51%
- PBT LESS OI(Q) Highest at Rs 1.15 cr.
3
With ROCE of 4.1, it has a Attractive valuation with a 1.5 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -100.00%, its profits have risen by 384% ; the PEG ratio of the company is 0
4
Below par performance in long term as well as near term
- Along with generating -100.00% returns in the last 1 year, the stock has also underperformed BSE500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Vaishali Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Vaishali Pharma for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Vaishali Pharma
-29.94%
-0.61
48.73%
Sensex
-4.77%
-0.35
13.44%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
13.04%
EBIT Growth (5y)
0.90%
EBIT to Interest (avg)
1.83
Debt to EBITDA (avg)
4.59
Net Debt to Equity (avg)
0.25
Sales to Capital Employed (avg)
1.39
Tax Ratio
20.96%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.35%
ROE (avg)
8.06%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
24
Industry P/E
Price to Book Value
1.58
EV to EBIT
34.65
EV to EBITDA
29.75
EV to Capital Employed
1.46
EV to Sales
1.17
PEG Ratio
0.03
Dividend Yield
NA
ROCE (Latest)
4.07%
ROE (Latest)
6.15%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend17What is working for the Company
ROCE(HY)
Highest at 8.38%
OPERATING PROFIT TO NET SALES(Q)
Highest at 6.51%
PBT LESS OI(Q)
Highest at Rs 1.15 cr.
PAT(Q)
Highest at Rs 1.49 cr.
EPS(Q)
Highest at Rs 0.11
-1What is not working for the Company
NET SALES(Q)
Lowest at Rs 22.89 cr
Loading Valuation Snapshot...
Here's what is working for Vaishali Pharma
Operating Profit Margin - Quarterly
Highest at 6.51%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 1.15 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 1.49 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 0.11
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Here's what is not working for Vaishali Pharma
Net Sales - Quarterly
Lowest at Rs 22.89 cr
in the last five quartersMOJO Watch
Near term sales trend is negative
Net Sales (Rs Cr)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
